Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Overweight 1Obesity 1Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 26Paclitaxel 25Carboplatin 19Bevacizumab 13Specimen Handling 11Magnetic Resonance Spectroscopy 9Doxorubicin 8Cisplatin 8Taxes 7Biopsy 7olaparib 6lenvatinib 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Megestrol Acetate 5Letrozole 5Gemcitabine 5Docetaxel 5trastuzumab deruxtecan 4Trastuzumab 4Tirzepatide 4Progestins 4Medroxyprogesterone Acetate 4Fluorouracil 4palbociclib 3ipatasertib 3atezolizumab 3abemaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × semaglutide × 90 days × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡